Clinical Trial Update: Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis C [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II trial evaluating an autologous dendritic cell vaccine transduced with an adenoviral NS3 vector for chronic hepatitis C was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Autologous dendritic cell vaccine transduced with adenoviral NS3 vector

Snippet

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra | Conditions: Hepatitis C, Chronic | Phase 1, Phase 2 | Status: TERMINATED